ReviewNature reviews. Disease primers2025
Brugada syndrome.
Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dietary and emotional triggers of ventricular fibrillation in Brugada syndrome: insights from a long-term subcutaneous implantable cardioverter-defibrillator case report.AME case reports · 2026Article
- The Utility of Genome-Wide Association Studies in Inherited Arrhythmias and Cardiomyopathies.Genes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brugada syndrome (BrS) is a cardiac channelopathy associated with an elevated risk of arrhythmias and sudden cardiac death compared with the general population. Since its initial description in 1992 by Pedro and Josep Brugada, there has been tremendous progress in our understanding and management of BrS. The condition is characterized by 'coved' ST segment elevations in the anterior precordial electrocardiogram leads, which occasionally requires additional pharmacological provocation for diagnosis. Substantial geographical variation in the prevalence, genetic characteristics and clinical behaviour of BrS exists. Improvements in the understanding of the genetic and molecular mechanisms of the condition have been made over the past 30 years, opening avenues for the discovery of diagnostic and management opportunities. In this Primer, we discuss the evolving epidemiology of BrS, the emerging genetic understanding of the condition, as well as its diagnosis and management. We summarize the major societal guideline recommendations pertaining to BrS and highlight the potential for technological advancements, such as digital health and machine learning, to improve patient care.
Indexed as
Identifiers
40442184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.